Andrew Fesnak, MD

Assistant Professor of Clinical Pathology and Laboratory Medicine
Perelman School of Medicine at the University of Pennsylvania

Contact InformationHospital of the University of Pennsylvania
3400 Spruce Street
3 Ravdin Building - R3067
Philadelphia, PA 19104

Office: 215-662-3325


Specialty Division

Transfusion Medicine & Therapeutic Pathology


BA (Molecular Biology), Princeton University, 2005
MD (Medical Doctorate), University of Medicine and Dentistry of New Jersey - Robert Wood Johnson School of Medicine, 2011
MHI (Masters of Health Care Innovation), University of Pennsylvania, 2019

Specialty Certification

Clinical Pathology, American Board of Pathology, 2014
Blood Banking / Transfusion Medicine, American Board of Pathology, 2015
Laboratory Management, Laboratory Management University, American Society for Clinical Pathology, 2015

Postgraduate Training

Resident, Clinical pathology, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2011-2014
Research fellow, Immunology, Perelman School of Medicine, University of Pennsylvania, 2012-2015
Clinical fellow, Transfusion medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2014-2015
Clinical fellow, Cell therapy, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2015-2016

Awards and Honors

Inductee, Gold Humanism Honor Society, 2011
The Kevin E. Salhany, MD Award for Excellence in Clinical Teaching, Department of Pathology and Laboratory Medicine Penn Medicine, 2016
Power of A Gold Award - AABB Cellular Therapies Certificate Program, American Society of Association Executives, 2019
SITC Team Science Award - Advanced T cell Engineering Against Malignancies (A-TEAM) team, Society for Immunotherapy of Cancer, 2020

Memberships and Professional Organizations

College of American Pathologists (CAP), 2011 - 2013
International Society for Cellular Therapy (ISCT), 2011 - Present
AABB, 2011 - Present
American Society for Clinical Pathology (ASCP), 2011 - Present
TerumoBCT, 2017 - 2017
Foundation for the Accreditation of Cellular Therapy (FACT), 2018 - Present
American Society for Apheresis (ASFA), 2018 - Present
National Heart, Blood and Lung Institute (NHLBI), 2019 - 2019

Web Links

Selected Publications

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Abou-el-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, SavoldoB, Blood Cancer Discov, 2021

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL, J Clin Oncol Online ahead of print(): , 2021, PMID:34156874

Read article

Discussion of the requirements, challenges and processing adaptations involved in an academic technology transfer of neo-antigen peptide pulsed peptide pulsed dendritic cells

Brennan AL, Guilliams J, Fox E, Carreno B, Linette G, Levine BL, Plesa G, Siegel D, Mackey S, Fesnak A, Cytotherapy 23(5): S173-S173, 2021

Clinical development of natural killer cells expressing chimeric antigen receptors

Gold RJ, Fesnak AD, Transfus Apher Sci 60(1): 103065, 2021, PMID:33468407

Read article

CAR T Cells: A Novel Biological Drug Class

Gladney W, Jadlowsky J, Davis MM, Fesnak A, Successful Drug Discovery, 2021

Limiting variability to achieve reproducibility in cell manufacturing

Lamontagne A, Fesnak A, Cell & Gene Therapy Insights 6(10): 1357-1363, 2020

The Challenge of Variability in Chimeric Antigen Receptor T Cell Manufacturing

Fesnak A, Regenerative Engineering and Translational Medicine 6(3): 322-329, 2020

Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells)

Xu J, Gohil M, Stadtmauer E, Fraietta JA, Gonzalez VE, Salas-McKee J, Jadlowsky J, Gladney W, Lamontagne A, Fesnak A, Siegel D, Levine BL, Lacey S, June C, Davis MM, Cytotherapy 22(5): S35-S36, 2020

Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products

Gladney W, Hexner E, Salas-McKee J, Fesnak A, Jadlowsky J, Plesa G, Leskowitz R, Chew A, Dai A, Gohil M, Xu J, Siegel D, Lacey S, Davis MM, June C, Cytotherapy 22(5): S35, 2020

CRISPR-engineered T cells in patients with refractory cancer

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH, Science, 2020, PMID:32029687

Read article

Search PubMed for articles